GT
MRNA icon

Glenmede Trust’s Moderna MRNA Stock Holding History

Glenmede Trust’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
19,377
+1,273
+7% +$65.9K 0.01% 687
2026
Q1 		$920K Buy
18,104
+470
+3% +$21.9K ﹤0.01% 761
2025
Q4 		$520K Buy
+17,634
New +$479K ﹤0.01% 929
2025
Q1 		– Sell
-5,570
Closed -$232K – 1418
2024
Q4 		$232K Buy
+5,570
New +$266K ﹤0.01% 1191
2024
Q3 		– Sell
-3,463
Closed -$411K – 1415
2024
Q2 		$411K Buy
3,463
+471
+16% +$59.6K ﹤0.01% 971
2024
Q1 		$319K Buy
+2,992
New +$302K ﹤0.01% 1043
2023
Q3 		– Sell
-3,184
Closed -$489K – 1333
2023
Q2 		$489K Hold
3,184
– – ﹤0.01% 838
2023
Q1 		$489K Sell
3,184
-397
-11% -$65.5K ﹤0.01% 842
2022
Q4 		$643K Buy
3,581
+1,444
+68% +$236K ﹤0.01% 767
2022
Q3 		$252K Buy
2,137
+181
+9% +$27.5K ﹤0.01% 1016
2022
Q2 		$278K Buy
1,956
+27
+1% +$3.86K ﹤0.01% 1020
2022
Q1 		$331K Sell
1,929
-752
-28% -$127K ﹤0.01% 1008
2021
Q4 		$680K Sell
2,681
-323
-11% -$94.4K ﹤0.01% 841
2021
Q3 		$1.16M Buy
3,004
+1,216
+68% +$448K 0.01% 663
2021
Q2 		$419K Sell
1,788
-2,050
-53% -$366K ﹤0.01% 931
2021
Q1 		$501K Buy
+3,838
New +$556K ﹤0.01% 847
2020
Q4 		– Sell
-1,641
Closed -$115K – 1840
2020
Q3 		$115K Sell
1,641
-96
-6% -$6.69K ﹤0.01% 1134
2020
Q2 		$111K Sell
1,737
-4,263
-71% -$233K ﹤0.01% 1130
2020
Q1 		$117K Hold
6,000
– – ﹤0.01% 1367
2019
Q4 		$117K Hold
6,000
– – ﹤0.01% 1367
2019
Q3 		$95K Buy
6,000
+3,000
+100% +$44.3K ﹤0.01% 1424
2019
Q2 		$43K Hold
3,000
– – ﹤0.01% 1751
2019
Q1 		$61K Buy
+3,000
New +$55.7K ﹤0.01% 1591

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Glenmede Trust's MRNA Position: Q2 2026 in Review

Glenmede Trust increased its Moderna (MRNA) stake by 7% in Q2 2026, buying an estimated $65.9K and bringing the position to 19,377 shares worth $1.36M. The position accounts for 0.01% of the portfolio, ranked #687.

Glenmede Trust first reported a position in MRNA in Q1 2019 and has held it in 23 quarters since. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Glenmede Trust held 19,377 shares of Moderna worth $1.36M as of Q2 2026.
  • Glenmede Trust bought 1,273 Moderna shares in Q2 2026, an estimated $65.9K.
  • Moderna made up 0.01% of Glenmede Trust's portfolio in Q2 2026, its #687 holding.
  • Glenmede Trust first reported a position in Moderna in Q1 2019 and has held it in 23 quarters since.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.